NIAID trial enrolling hospital patients in remdesivir combination therapies
Over the next several months, the National Institute of Allergy and Infectious Diseases expects to enroll up to 1,500 adult COVID-19 hospital patients who require supplemental oxygen in a global clinical trial that aims to determine whether baricitinib or dexamethasone is more effective at preventing mechanical ventilation or death when administered with remdesivir. One group of participants will receive dexamethasone and remdesivir, and another group will receive remdesivir and baricitinib.
Related News Articles
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…